2024 MIIF China: Bridging the Present and Future of Laboratory Diagnostics

Connecting ideas and wisdom from experts worldwide

The MIIF, debuted in 2011, has brought together over one thousand laboratory experts from more than one hundred countries to exchange the latest knowledge and best practices in laboratory diagnostics. This year, at 2024 MIIF China on April 23-24, jointly organized by IFCC, EFLM, SIBioC, and Mindray, over two hundred laboratory professionals from around the world have gathered to explore the latest advancements and upcoming trends in the field. Covering a diverse range of topics from novel biomarkers to cutting-edge diagnostic technologies, the forum provides a peek into the future landscape of the industry through insightful discussions.

The academic forum has showcased brilliant ideas, with experts from industry associations such as IFCC, EFLM, and SIBioC, as well as renowned universities, presenting their insights and latest research findings on various topics. These topics include new cardiac biomarkers, digital morphology, and laboratory development and accreditation. During their presentation of research studies, the speakers noted the superior performance of Mindray's products and their clinical value in early disease diagnosis, specifically highlighting the high-sensitive troponin I, digital morphology and SF Cube technology, all supported by evaluation data. They also pointed out the innovative technology implemented in Mindray solutions, contributing to improved laboratory efficiency and productivity.

At the Roundtable Discussion themed "Innovation at Heart", experts discussed the clinical value of cardiac biomarkers such as the high-sensitive troponin I and future perspectives on novel cardiac marker research. Dr. He Jianwen, Chief Scientist of Mindray In-Vitro Diagnostics, highlighted Mindray's close integration with clinical settings, rigorous validation of clinical applications, and continuous innovation to meet growing demands. The recent launch of the high-sensitive troponin I, endorsed by top experts globally, demonstrates Mindray's latest achievement in addressing clinical challenges in cardiovascular disease.

Collaborating towards a more intelli-digital future

While we are emboldened by increasingly sophisticated technologies such as artificial intelligence and information technologies, we are mindful of the challenges that lie ahead. Inspired by the new wave of laboratory digitization and intellectualization, Mindray is excited to introduce the "Lab Vision 2030" initiative at the MIIF.

Beyond Management

The digitization of laboratory diagnostics will not just be a trend, but a reality. By harnessing the power of cutting-edge technology, including big data, AI, and IT solutions, coupled with Mindray automated systems, we are working towards a digital future where laboratories can unleash their potential to the fullest, achieving increased productivity and overall performance improvements.

Beyond Diagnosis

Diagnostic data exceeds numerical values, bridging the gap between lab tests and clinical decisions. The trend towards closer collaboration and an interdisciplinary approach will further enhance patient outcomes. Mindray will continue to utilize its comprehensive product portfolio and innovative capabilities, driven by ongoing investment in research and development and clinical partnerships with leading research institutions, to offer customized solutions that effectively meet real clinical needs.

Beyond Education

Education is not an end goal, but a means to drive progress in the industry. Academic communication and talent cultivation should be geared towards effectively addressing the evolving need for improved healthcare. Leveraging our extensive global academic resources, Mindray will keep collaborating with renowned institutions and industry organizations to promote academic exchange and nurture laboratory talents, effectively addressing the industry’s evolving demands.

New serum solutions for mid-volume labs

At the event, Mindray also held a grand launch event for the new serum solutions designed for mid-volume laboratories, comprising two stand-alone analyzers (CL-2600i & BS-1000M) and two integrated solutions (M680 & M980). With their compact design and high efficiency, these new products showcase Mindray's ongoing commitment to innovation in chemiluminescence immunoassay and clinical chemistry technologies.